Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series

2002 ◽  
Vol 109 (9) ◽  
pp. 1020-1024 ◽  
Author(s):  
V.A. Rodie ◽  
A.J. Thomson ◽  
F.M. Stewart ◽  
A.J. Quinn ◽  
I.D. Walker ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Case Series ◽  
Low Molecular Weight ◽  
In Pregnancy

Low Molecular Weight Heparin for the Treatment of Venous Thromboembolism in Pregnancy: A Case Series

2003 ◽  
Vol 58 (3) ◽  
pp. 153-155
Author(s):  
V. A. Rodie ◽  
A. J. Thomson ◽  
F. M. Stewart ◽  
A. J. Quinn ◽  
I. D. Walker ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Case Series ◽  
Low Molecular Weight ◽  
In Pregnancy

scholarly journals Thromboembolism and antithrombotic management in pregnancy

2011 ◽  
Vol 152 (21) ◽  
pp. 815-821 ◽  
Author(s):  
Attila Pajor
Keyword(s):  
Risk Factors ◽  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Individual Risk ◽  
Low Molecular Weight ◽  
Pregnancy And Delivery ◽  
Individual Risk Factors ◽  
In Pregnancy

Venous thromboembolism occurs approximately in 1 of 1000 pregnancies. It is one of the leading causes of maternal mortality. Physiologic changes associated with pregnancy and delivery favor for developing venous thromboembolism, and there are individual risk factors, too, contributing to its manifestation. The most frequent risk factors of venous thromboembolism developing during pregnancy are the previous venous thromboembolism and the thrombophilias, furthermore, some other diseases and some unique complications of pregnancy and delivery. Beyond mechanical prevention only heparin preparations can be used for preventing and treating venous thromboembolism in pregnancy and among them the low-molecular-weight heparins are preferred for applying. Dosage of low-molecular-weight heparin preparations is determined by the type and strength of thrombophilia. For treatment of venous thromboembolism presented during pregnancy subcutaneous 100 IU/kg low-molecular-weight heparin is generally used at every 12 hours. Postpartum the oral anticoagulants can be safely applied, too. Orv. Hetil., 2011, 152, 815–821.

scholarly journals Severe antithrombin deficiency in pregnancy: Achieving adequate anticoagulation

2018 ◽  
Vol 12 (1) ◽  
pp. 45-51 ◽  
Author(s):  
Ben Pearson-Stuttard ◽  
Catherine Bagot ◽  
Etienne Ciantar ◽  
Bethan Myers ◽  
Rosalyn Davies ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Case Series ◽  
Low Molecular Weight ◽  
Factor X ◽  
Antithrombin Deficiency ◽  
History Of ◽  
High Doses ◽  
Elective Termination

Antithrombin deficiency is identified as one of the most potent risk factors for venous thromboembolism during pregnancy. Therapeutic low molecular weight heparin is recommended, but it can be difficult to attain sufficient anticoagulation since low molecular weight heparin requires antithrombin to exert its anticoagulant effect. We carried out a multicentre case-series assessing the dose of low molecular weight heparin required to achieve therapeutic anti-activated factor X levels in pregnant women with antithrombin deficiency. We assessed 27 pregnancies in 18 women with severe antithrombin deficiency, which we defined as an antithrombin level of <0.55 IU/ml (with or without prior venous thromboembolism) or an antithrombin level < 0.8 IU/ml and a personal history of venous thromboembolism. Our data illustrate the need for high doses of low molecular weight heparin to achieve therapeutic anti-activated factor X levels (average 20,220 IU/day). All pregnancies ended in live birth (excluding one elective termination), although intrauterine growth restriction occurred in five (18%).

scholarly journals Pulmonary thrombo-embolism in pregnancy: diagnosis and management

Breathe ◽  
2015 ◽  
Vol 11 (4) ◽  
pp. 282-289 ◽  
Author(s):  
Louise E. Simcox ◽  
Laura Ormesher ◽  
Clare Tower ◽  
Ian A Greer
Keyword(s):  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Pulmonary Thromboembolism ◽  
Total Duration ◽  
Bleeding Risk ◽  
Low Molecular Weight ◽  
List Type ◽  
Diagnosis And Management ◽  
In Pregnancy

Key pointsVenous thromboembolism (VTE) in pregnancy remains a leading cause of direct maternal mortality in the developed world and identifiable risk factors are increasing in incidence.VTE is approximately 10-times more common in the pregnant population (compared with non-pregnant women) with an incidence of 1 in 1000 and the highest risk in the postnatal period.If pulmonary imaging is required, ventilation perfusion scanning is usually the preferred initial test to detect pulmonary embolism within pregnancy. Treatment should be commenced on clinical suspicion and not be withheld until an objective diagnosis is obtained.The mainstay of treatment for pulmonary thromboembolism in pregnancy is anticoagulation with low molecular weight heparin for a minimum of 3 months in total duration and until at least 6 weeks postnatal. Low molecular weight heparin is safe, effective and has a low associated bleeding risk.Educational aimsTo inform readers about the current guidance for diagnosis and management of pulmonary thromboembolism in pregnancy.To highlight the risks of venous thromboembolism during pregnancy.To introduce the issues surrounding management of pulmonary thromboembolism around labour and delivery

Sign in / Sign up

Export Citation Format

Share Document